Barbara Kramar

Oct 16, 2024 | mdpi.com | Barbara Kramar |Tinkara Pirc Marolt |Irina Milisav |María Mónica Monsalve

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Jul 2, 2024 | preprints.org | Barbara Kramar |Tinkara Pirc Marolt |Irina Milisav |María Mónica Monsalve

PreprintArticleVersion 1This version is not peer-reviewedVersion 1: Received: 30 June 2024 / Approved: 1 July 2024 / Online: 2 July 2024 (13:23:11 CEST)Kramar, B.; Marolt, T. P.; Goler, A. M. Y.; Šuput, D.; Milisav, I.; Monsalve, M. Aripiprazole, but Not Olanzapine, Alters the Response to Oxida-Tive Stress, Reducing the Activation of Mitogen-Activated Protein Kinases (MAPKs) and Promoting Cell Survival in FAO Cells. Preprints 2024, 2024070129.

Oct 30, 2023 | mdpi.com | Barbara Kramar |Andrej Vovk |Helena Podgornik |Tinkara Pirc Marolt

1. IntroductionAripiprazole (ARI) is an antipsychotic drug for treating mental disorders such as schizophrenia and bipolar disorder. It has fewer side effects than other frequently used second-generation antipsychotics [1]. Nevertheless, the adverse effects include impulsive and compulsive behaviours, such as uncontrollable urges to gamble, overeat, or shop [2].